{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:29:08Z","timestamp":1722893348019},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,12,13]],"date-time":"2005-12-13T00:00:00Z","timestamp":1134432000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1038\/sj.bjc.6602910","type":"journal-article","created":{"date-parts":[[2006,1,10]],"date-time":"2006-01-10T13:12:13Z","timestamp":1136898733000},"page":"55-61","source":"Crossref","is-referenced-by-count":7,"title":["SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel\u2013irinotecan as first-line therapy for ovarian cancer"],"prefix":"10.1038","volume":"94","author":[{"name":"for the Scottish Gynaecological Cancer Trials Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A R","family":"Clamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"M\u00e4enp\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Cruickshank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P M","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Vasey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Sorbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Hindley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G C","family":"Jayson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,12,13]]},"reference":[{"key":"BF6602910_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1200\/JCO.2003.02.091","volume":"21","author":"DC Bodurka","year":"2003","unstructured":"Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM (2003) Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 21: 291\u2013297","journal-title":"J Clin Oncol"},{"key":"BF6602910_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1006\/gyno.2001.6179","volume":"81","author":"G Bolis","year":"2001","unstructured":"Bolis G, Scarfone G, Villa A, Parazzini F (2001) Phase II trial of topotecan, carboplatin and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer. Gynecol Oncol 81: 331\u2013333","journal-title":"Gynecol Oncol"},{"key":"BF6602910_CR3","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jama.1995.03520310040027","volume":"273","author":"G Bonadonna","year":"1995","unstructured":"Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273: 542\u2013547","journal-title":"JAMA"},{"key":"BF6602910_CR4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1200\/JCO.2004.01.106","volume":"22","author":"L Butler","year":"2004","unstructured":"Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A (2004) Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 22: 2461\u20132468","journal-title":"J Clin Oncol"},{"key":"BF6602910_CR5","first-page":"84","volume":"21","author":"N Cacciari","year":"2000","unstructured":"Cacciari N, Zamagni C, Martoni A (2000) The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer: is it possible only with peripheral blood stem support? Eur J Gynaecol Oncol 21: 84\u201385","journal-title":"Eur J Gynaecol Oncol"},{"key":"BF6602910_CR6","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748\u20131756","journal-title":"J Clin Oncol"},{"key":"BF6602910_CR7","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1200\/JCO.2004.09.088","volume":"22","author":"S De Placido","year":"2004","unstructured":"De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Carteni G, Manzione L, Febbraro A, de Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S (2004) Topotecan compared with no therapy after response to surgery and carboplatin\/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22: 2635\u20132642","journal-title":"J Clin Oncol"},{"key":"BF6602910_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2003.10.003","volume":"92","author":"P Escobar","year":"2004","unstructured":"Escobar P, Markman M, Rose P, Zanotti K, Webster K, Belinson J (2004) Phase 2 trial of carboplatin, paclitaxel and irinotecan in ovarian, fallopian tube and primary peritoneal cancers. Gynecol Oncol 92: 192\u2013196","journal-title":"Gynecol Oncol"},{"key":"BF6602910_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143\u2013151","journal-title":"Biometrics"},{"key":"BF6602910_CR10","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312\u20133322","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"BF6602910_CR11","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1038\/sj.bjc.6601496","volume":"89","author":"JP Guastalla III","year":"2003","unstructured":"Guastalla III JP, Dieras V (2003) The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer 89 (Suppl 3): S16\u2013S22","journal-title":"Br J Cancer"},{"key":"BF6602910_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/sj.bjc.6601618","volume":"90","author":"AE Guppy","year":"2004","unstructured":"Guppy AE, Nelstrop AE, Foster T, Agarwal R, Seckl MJ, Rustin GJS (2004) A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. Br J Cancer 90: 810\u2013814","journal-title":"Br J Cancer"},{"key":"BF6602910_CR13","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.bjc.6602000","volume":"91","author":"M Harries","year":"2004","unstructured":"Harries M, Moss C, Perren T, Gore M, Hall G, Everard M, A\u2019Hern R, Gibbens I, Jenkins A, Shah R, Cole C, Pizzada O, Kaye S (2004) A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer 91: 627\u2013632","journal-title":"Br J Cancer"},{"key":"BF6602910_CR14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1200\/JCO.1999.17.3.747","volume":"17","author":"VM Herben","year":"1999","unstructured":"Herben VM, Panday VR, Richel DJ, Schellens JH, van der Vange N, Rosing H, Beusenberg FD, Hearn S, Doyle E, Beijnen JH, ten Bokkel Huinink WW (1999) Phase I and pharmacologic study of the combination of paclitaxel, cisplatin and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. J Clin Oncol 17: 747\u2013755","journal-title":"J Clin Oncol"},{"key":"BF6602910_CR15","doi-asserted-by":"crossref","unstructured":"International Collaborative Ovarian Neoplasm Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505\u2013515","DOI":"10.1016\/S0140-6736(02)09738-6"},{"key":"BF6602910_CR16","first-page":"567","volume":"50","author":"JE Kurtz","year":"2003","unstructured":"Kurtz JE, Negrier S, Husseini F, Limacher JM, Borel C, Wagner JP, Prevot G, Bergerat JP, Dufour P (2003) A phase II study of docetaxel\u2013irinotecan combination in advanced pancreatic cancer. Hepatogastroenterology 50: 567\u2013570","journal-title":"Hepatogastroenterology"},{"key":"BF6602910_CR17","first-page":"403","volume":"18","author":"J M\u00e4enp\u00e4\u00e4","year":"2002","unstructured":"M\u00e4enp\u00e4\u00e4 J, Ala-Fossi S-L, Kivinen S, Pohto M, K\u00e4\u00e4r K, Jehunen A (2002) Docetaxel and irinotecan in the second-line treatment of ovarian cancer: final results of a phase II study. Proc Am Soc Clin Oncol 18: 403 (Abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 4","key":"BF6602910_CR18","first-page":"69","volume":"9","author":"J M\u00e4enp\u00e4\u00e4","year":"1998","unstructured":"M\u00e4enp\u00e4\u00e4 J, Hagman E, Kivinen S, Pohto M, K\u00e4\u00e4r K, Jekunen A (1998) The combination of taxotere and campto for second line treatment of ovarian cancer \u2013 a phase I dose finding study. Ann Oncol 9 (Suppl 4): 69 (Abstract)","journal-title":"Ann Oncol"},{"key":"BF6602910_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1\u20136","journal-title":"N Engl J Med"},{"key":"BF6602910_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","volume":"18","author":"FM Muggia","year":"2000","unstructured":"Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 18: 106\u2013115","journal-title":"J Clin Oncol"},{"key":"BF6602910_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/annonc\/mdi053","volume":"16","author":"D Pectasides","year":"2005","unstructured":"Pectasides D, Pectasides M, Farmakis D, Kostopoulou V, Nikolaou M, Gaglia A, Koumppou M, Mylonakis N, Xiros N, Economopoulos T, Raptis SA (2005) Comparison of docetaxel and docetaxel\u2013irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 16: 294\u2013299","journal-title":"Ann Oncol"},{"issue":"16S","key":"BF6602910_CR22","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1200\/jco.2005.23.16_suppl.lba5007","volume":"23","author":"J Pfisterer","year":"2005","unstructured":"Pfisterer J, Weber B, du Bois A, Lortholary A, Schade-Brittinger C, Wagner U, Bourgeois H, Jakisch C, Moebus V, Mayer F (2005) Paclitaxel\/carboplatin vs. paclitaxel\/carboplatin followed by topotecan in first-line treatment of advanced ovarian cancer. Mature results of a gynecologic cancer intergroup phase III trial of the AGO OVAR and GINECO. J Clin Oncol 23 (16S): 5007","journal-title":"J Clin Oncol"},{"key":"BF6602910_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"M Piccart","year":"2000","unstructured":"Piccart M, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S (2000) Randomized intergroup trial of cisplatin\u2013paclitaxel versus cisplatin\u2013cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699\u2013708","journal-title":"J Natl Cancer Inst"},{"key":"BF6602910_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/jnci\/djh081","volume":"96","author":"GJ Rustin","year":"2004","unstructured":"Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J (2004) New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 96: 487\u2013488","journal-title":"J Natl Cancer Inst"},{"key":"BF6602910_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1471-2407-2-37","volume":"2","author":"K Shibuya","year":"2002","unstructured":"Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ (2002) Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2: 37","journal-title":"BMC Cancer"},{"key":"BF6602910_CR26","first-page":"1681","volume":"18","author":"S Takeuchi","year":"1991","unstructured":"Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y, Tamaya T (1991) A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Gan To Kagaku Ryoho 18: 1681\u20131689","journal-title":"Gan To Kagaku Ryoho"},{"key":"BF6602910_CR27","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/jnci\/djh323","volume":"96","author":"PA Vasey","year":"2004","unstructured":"Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, the Scottish Gynaecological Cancer Trials Group (2004) Phase III randomized trial of docetaxel\u2013carboplatin versus paclitaxel\u2013carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682\u20131691","journal-title":"J Natl Cancer Inst"},{"key":"BF6602910_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/sj.bjc.6602268","volume":"92","author":"FM Wachters","year":"2005","unstructured":"Wachters FM, Groen HJM, Biesma B, Schramel FMNH, Postmus PE, Stigt JA, Smit EF (2005) A randomised phase II trial of docetaxel vs docetaxel\u2013irinotecan in patients with stage IIIb\u2013IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 92: 15\u201320","journal-title":"Br J Cancer"},{"key":"BF6602910_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nm0196-72","volume":"2","author":"AF Wahl","year":"1996","unstructured":"Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2\/M arrest and apoptosis. Nat Med 2: 72\u201379","journal-title":"Nat Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602910.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602910","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602910.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:19:22Z","timestamp":1684397962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,13]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["BF6602910"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602910","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2005,12,13]]}}}